Medpace Holdings Inc vs Newegg Commerce Inc — how do they compare? Medpace Holdings Inc trades at $533.39 (market cap $15.08B), while Newegg Commerce Inc trades at $13.52 (market cap $270.98M). The key difference: Medpace Holdings Inc is far larger — about 55.6× Newegg Commerce Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | NEGG | |
|---|---|---|
Market Cap | $15.08B | $270.98M |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $128.09 |
52-Week Low | $308.88 | $12.92 |
Enterprise Value | $14.55B | $269.78M |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
NEGG trades at $13.12, up 1.0% today, with a bearish technical outlook despite oversold RSI readings. The company shows improving fundamentals, with Q1 2026 EPS beating expectations and revenue stabilizing near $1.4B, though net margins remain thin at 0.39%. Recent news highlights product launches and AI shopping enhancements, signaling innovation efforts. Cash flow trends are volatile, with 2025 net cash flow positive at $8.91M but 2026 projecting a significant outflow.
The stock presents a mixed outlook: low P/S ratio of 0.19 suggests undervaluation relative to sales, but high P/E of 49.72 and consistent net losses pose risks. Analyst sentiment is bullish with a 100% buy rating, yet technical weakness and competitive e-commerce pressures require caution. Near-term catalysts include execution on profitability and AI initiatives, but investor patience is needed for sustained turnaround.
Trailing returns across standard periods
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →